Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma
Preemptive plerixafor passes the cost-utility guidelines to be used in MM patients in Brazil, potentially guiding policy decisions on resource allocation within the national health system.
Authors
- Alessandro Gonçalves Campolina (ORCID: https://orcid.org/0000-0002-0233-0797)
- Roselene Mesquita Augusto Passos (ORCID: https://orcid.org/0000-0002-9509-5043)
- Juliana de Oliveira Martins
- Tallys Kalynka Feldens (ORCID: https://orcid.org/0000-0002-1804-8315)
- Cesar de Almeida Neto
Institutions
- Universidade Tecnológica Federal do Paraná (BR)
- Scuola Superiore Sant'Anna (IT)
- Universidade de São Paulo (BR)
- Dr. Euryclides Hospital de Jesus Zerbini (BR)
- Centre for Health Technology and Services Research (PT)
- Fundação Pró-Sangue Hemocentro de São Paulo (BR)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1080/14737167.2026.2612985
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00